{"id":{"repo_id":"rosario","oai_identifier":"oai:repository.urosario.edu.co:10336/18871"},"canonical_url":"https://search.dev.ndltd.org/etd/rosario/oai:repository.urosario.edu.co:10336/18871","repository":{"repo_id":"rosario","name":"Universidad del Rosario","base_url":"https://repository.urosario.edu.co/oai/request"},"display":{"title":"Fibrolamellar Hepatocellular Carcinoma and Noncirrhotic Hyperammonemic Encephalopathy","abstract":"Fibrolamellar hepatocarcinoma is an infrequent liver tumor, currently considered to be a variant different from hepatocarcinoma. The differences lie in genomic alterations, a greater prevalence of fibrolamellar hepatocarcinoma in young patients, and its lack of association with underlying liver disease. The clinical presentation is unspecific, with symptoms ranging from abdominal pain, malaise, and weight loss to atypical manifestation which include hyperammonemic encephalopathy. We present the case of a 33-year-old woman with no prior medical history who presented with a coma and a diagnosis of inoperable fibrolamellar hepatocarcinoma requiring a cadaver donor transplant. While she was on the waiting list, she received hemofiltration and ammonium benzoate treatment, with progressive improvement in her state of consciousness.","abstract_html":"Fibrolamellar hepatocarcinoma is an infrequent liver tumor, currently considered to be a variant different from hepatocarcinoma. The differences lie in genomic alterations, a greater prevalence of fibrolamellar hepatocarcinoma in young patients, and its lack of association with underlying liver disease. The clinical presentation is unspecific, with symptoms ranging from abdominal pain, malaise, and weight loss to atypical manifestation which include hyperammonemic encephalopathy. We present the case of a 33-year-old woman with no prior medical history who presented with a coma and a diagnosis of inoperable fibrolamellar hepatocarcinoma requiring a cadaver donor transplant. While she was on the waiting list, she received hemofiltration and ammonium benzoate treatment, with progressive improvement in her state of consciousness.","abstract_has_math":false,"creators":["Suarez, Oscar","Pérez, María","Garzón Olarte, Martín Alonso","Daza, Rodrigo","Hernandez, Geovanny","Salinas, Carolina","Ceballos, Jorge","De Leon, Enrique P.","Mugnier, Jacqueline","Beltrán, Oscar","Varón, Adriana"],"institution":"Universidad del Rosario","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-12-03","date_published":"2018-12-03","updated_at":"2026-07-27T20:46:13Z","subjects":["Fibrolamellar hepatocellular carcinoma","Noncirrhotic hyperammonemic encephalopathy","Enfermedades","Hepatocarcinoma fibrolamelar","Enfermedades hepáticas"],"languages":["spa"],"rights":["info:eu-repo/semantics/openAccess"],"rights_urls":["http://creativecommons.org/licenses/by-nc-nd/2.5/co/"],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["http://repository.urosario.edu.co/handle/10336/18871"],"render_values":[{"text":"http://repository.urosario.edu.co/handle/10336/18871","href":"http://repository.urosario.edu.co/handle/10336/18871","code":true}]}]},"links":{"outbound_url":"https://doi.org/10.48713/10336_18871","outbound_label":"DOI","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Pérez, María"]},{"key":"dc:creator","label":"Author","values":["Suarez, Oscar","Pérez, María","Garzón Olarte, Martín Alonso","Daza, Rodrigo","Hernandez, Geovanny","Salinas, Carolina","Ceballos, Jorge","De Leon, Enrique P.","Mugnier, Jacqueline","Beltrán, Oscar","Varón, Adriana"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2018-12-03","2019-01-11T22:07:53Z"]},{"key":"dc:publisher","label":"Institution","values":["Universidad del Rosario","Facultad de Medicina","Especialización en Gastroenterología"]},{"key":"dc:type","label":"Dc Type","values":["info:eu-repo/semantics/masterThesis","info:eu-repo/semantics/acceptedVersion"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Fibrolamellar hepatocellular carcinoma","Noncirrhotic hyperammonemic encephalopathy","Enfermedades","Hepatocarcinoma fibrolamelar","Enfermedades hepáticas"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["spa"]},{"key":"dc:rights","label":"Dc Rights","values":["info:eu-repo/semantics/openAccess","http://creativecommons.org/licenses/by-nc-nd/2.5/co/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://doi.org/10.48713/10336_18871","http://repository.urosario.edu.co/handle/10336/18871"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Fibrolamellar hepatocarcinoma is an infrequent liver tumor, currently considered to be a variant different from hepatocarcinoma. The differences lie in genomic alterations, a greater prevalence of fibrolamellar hepatocarcinoma in young patients, and its lack of association with underlying liver disease. The clinical presentation is unspecific, with symptoms ranging from abdominal pain, malaise, and weight loss to atypical manifestation which include hyperammonemic encephalopathy. We present the case of a 33-year-old woman with no prior medical history who presented with a coma and a diagnosis of inoperable fibrolamellar hepatocarcinoma requiring a cadaver donor transplant. While she was on the waiting list, she received hemofiltration and ammonium benzoate treatment, with progressive improvement in her state of consciousness.","UNIVERSIDAD DEL ROSARIO"]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:source","label":"Dc Source","values":["H.A.Edmondson,“Differentialdiagnosisoftumorsandtumorlikelesionsofliverininfancyandchildhood,”A.M.A.American JournalofDiseasesofChildren,vol.91,no.2,pp.168–186,1956.","V.Maniaci,B.R.Davidson,K.Rollesetal.,“Fibrolamellarhepatocellularcarcinoma-Prolongedsurvivalwithmultimodality therapy,”European Journal of Surgical Oncology, vol. 35,no. 6, pp.617–621,2009.","M.Torbenson,“FibrolamellarCarcinoma:2012Update,”Scientifica,vol.2012,ArticleID743790,15pages,2012.","E.J.GrossmanandJ.M.Millis,“Livertransplantationfornonhepatocellularcarcinomamalignancy:indications,limitations, andanalysisofthecurrentliterature,”LiverTransplantation,vol. 16,no.8,pp.930–942,2010.","V. Paradis, “Histopathology of hepatocellular carcinoma,” in Multidisciplinary Treatment of Hepatocellular Carcinoma, vol. 190 of Recent Results in Cancer Research, pp. 21–32, Springer, Berlin,Germany,2013.","G. M. Fonseca, A. D. Varella, F. F. Coelho, E. S. Abe, R. B. Dumarco, and P. Herman, “Downstaging and resection after neoadjuvant therapyfor fibrolamellar hepatocellularcarcinoma,”WorldJournalofGastrointestinalSurgery,vol.6,no.6, p.107,2014.","D.Ganeshan,J.Szklaruk,V.Kundra,A.Kaseb,A.Rashid,and K. Elsayes, “Imaging features of fibrolamellar hepatocellular carcinoma,”AmericanJournalofRoentgenology,vol.202,no.3, pp.544–552,2014.","T.Eggert,K.A.McGlynn,A.Duffy,M.P.Manns,T.F.Greten, andS.F.Altekruse,“Fibrolamellarhepatocellularcarcinomain theUSA,2000–2010:adetailedreportonfrequency,treatment andoutcomebasedonthesurveillance,epidemiology,andend Results database,” United European Gastroenterology Journal, vol.1,no.5,pp.351–357,2013.","H.Cornella,C.Alsinet,S.Sayolsetal.,“Uniquegenomicprofile of fibrolamellar hepatocellular carcinoma,” Gastroenterology, vol.148,no.4,pp.806–818.e10,2015.","G. G. Malouf, S. Job, V. Paradis et al., “Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrinesignature,”Hepatology,vol.59,no.6,pp.2228–2237, 2014.","T. Pawlik and K. Lafaro, “Fibrolamellar hepatocellular carcinoma: current clinical perspectives,” Journal of Hepatocellular Carcinoma,p.151.","T. Kanai, T. Takabayashi, Y. Kawano, S. Kuramochi, and N. Miyazawa,“Acaseofpostoperativerecurrenceoffibrolamellar hepatocellular carcinoma with increased vitamin B12 binding capacityinayoungJapanesefemale,”JapaneseJournalofClinical Oncology,vol.34,no.6,pp.346–351,2004.","S. K. Asrani and N. F. Larusso, “Fibrolamellar hepatocellular carcinoma presenting with budd-chiari syndrome, right atrial thrombus, and pulmonary emboli,” Hepatology, vol. 55, no. 3, pp.977-978,2012.","J.Lloreta,C.Vadell,X.Fabregat,andS.Serrano,“Fibrolamellar hepatictumorwithneurosecretoryfeaturesandsystemicdepositionofAAamyloid,”UltrastructuralPathology,vol.18,no.1-2, pp.287–292,1994.","J. A. Espinosa, A. Merlo, M.-O. Arafeh, and G. Munene, “An unusualcaseofjaundice:Biliarytumorthrombusinfibrolamellar hepatocellular carcinoma,” International Journal of Surgery CaseReports,vol.36,pp.50–54,2017.","K. M. Tezer, B. Yalc ¸´ın, N. B¨ uy¨ukpamukc¸u, G. Kale, and M. B¨uy¨ukpamukc¸u,“Fibrolamellarhepatocellularcarcinomawith skeletalmetastases,”PediatricHematologyandOncology,vol.18, no.4,pp.273–278,2001.","N.A.Villa,R.Pannala,D.O.Faigeletal.,“Metastaticfibrolamellar hepatocellular carcinoma to the pancreas,” Case Reports in Gastroenterology,vol.9,pp.266–271,2015.","S.H.Ciurea,E.Matei,C.S.Stanescuetal.etal.,“Fibrolamellar hepatocellularcarcinomawithovarianmetastasis-anunusual presentation.Rom,”JournalofMorphologyandEmbryology,vol. 58,pp.187-92,2017.","O.Soreide,A.Czemiak,H.Bradpiece,S.Bloom,andL.Blumgart,“Characteristicsoffibrolamellarhepatocellularcarcinoma. A study of nine cases and a review of the literature,” The AmericanJournalofSurgery,vol.151,no.4,pp.518–523,1986.","D. L. Lildballe, K. Q. T. Nguyen, S. S. Poulsen, H. O. Nielsen, and E. Nexo, “Haptocorrin as marker of disease progression infibrolamellarhepatocellularcarcinoma,”EuropeanJournalof SurgicalOncology,vol.37,no.1,pp.72–79,2011.","R. K. G. Do, A. McErlean, C. S. Ang, R. P. Dematteo, and G. K. Abou-Alfa, “CT and MRI of primary and metastatic fibrolamellar carcinoma: A case series of 37 patients,” British JournalofRadiology,vol.87,no.1040,ArticleID20140024,2014.","S. Liu, K. Wah Chan, J. Tong, Y. Wang, B. Wang, and L. Qiao, “PET-CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellularcarcinoma:A casereport and a summaryofrecentliterature,”QJM:AnInternationalJournalof Medicine,vol.104,no.6,pp.477–483,2011.","C.G.Roth andD.G.Mitchell,“Hepatocellularcarcinomaand otherhepaticmalignancies:MRimaging,”RadiologicClinicsof NorthAmerica,vol.52,no.4,pp.683–707,2014.","S. Sethi, N. Tageja, J. Singh et al., “Hyperammonemic encephalopathy:Ararepresentationoffibrolamellarhepatocellularcarcinoma,”TheAmericanJournaloftheMedicalSciences , vol.338,no.6,pp.522–524,2009.","C. Berger, P. Dimant, L. Hermida, F. Paulin, M. Pereyra, and M.Tejo,“Hyperammonemicencephalopathyandfibrolamellar hepatocellularcarcinoma,”Medicina(Argentina),vol.72,no.5, pp.425–427,2012.","R. A. Sulaiman and T. Geberhiwot, “Fibrolamellar Hepatocellular Carcinoma Mimicking Ornithine Transcarbamylase Deficiency,”inJIMDReportsVolume16,vol.16ofJIMDReports, pp.47–50,SpringerBerlinHeidelberg,Berlin,Heidelberg,2014.","C. I. Chapuy, I. Sahai, R. Sharma, A. X. Zhu, and O. N. Kozyreva,“Hyperammonemicencephalopathyassociatedwith fibrolamellar hepatocellular carcinoma: Case report, literature review,andproposedtreatmentalgorithm,”TheOncologist,vol. 21,no.4,pp.514–520,2016.","M. N. Mavros, S. C. Mayo, O. Hyder, and T. M. Pawlik, “A systematic review: Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma,” Journal of the AmericanCollegeofSurgeons,vol.215,no.6,pp.820–830,2012.","W. T. Kassahun, “Contemporary management of fibrolamellar hepatocellular carcinoma: Diagnosis, treatment, outcome, prognosticfactors,andrecentdevelopments,”WorldJournalof SurgicalOncology,vol.14,no.1,articleno.151,2016.","A. D. Pinna, S. Iwatsuki, R. G. Lee et al., “Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation,”Hepatology,vol.26,no.4,pp.877–883,1997.","L.G.Atienza,J.Berger,X.Meietal.,“Livertransplantationfor fibrolamellarhepatocellularcarcinoma:Anationalperspective,” JournalofSurgicalOncology,vol.115,no.3,pp.319–323,2017.","A.O.Kaseb,M.Shama,I.H.Sahinetal.,“Prognosticindicators and treatmentoutcome in94 casesof fibrolamellar hepatocellularcarcinoma,”Oncology(Switzerland),vol.85,no.4,pp.197– 203,2013.","B. Njei, “Fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: Better 5-year survival or artifactualresultofresearchmethodology?”Gut,vol.63,no.9, pp.1374-1375,2014","A. E. Alsina, “Successful Liver Transplantation for HyperammonemicFibrolamellarHepatocellularCarcinoma,”ACGCase ReportsJournal,vol.3,no.4,2016","instname:Universidad del Rosario","reponame:Repositorio Institucional EdocUR"]},{"key":"dc:title","label":"Title","values":["Fibrolamellar Hepatocellular Carcinoma and Noncirrhotic Hyperammonemic Encephalopathy"]}]}],"canonical_facts":{"dc:contributor":["Pérez, María"],"dc:creator":["Suarez, Oscar","Pérez, María","Garzón Olarte, Martín Alonso","Daza, Rodrigo","Hernandez, Geovanny","Salinas, Carolina","Ceballos, Jorge","De Leon, Enrique P.","Mugnier, Jacqueline","Beltrán, Oscar","Varón, Adriana"],"dc:date":["2018-12-03","2019-01-11T22:07:53Z"],"dc:description":["Fibrolamellar hepatocarcinoma is an infrequent liver tumor, currently considered to be a variant different from hepatocarcinoma. The differences lie in genomic alterations, a greater prevalence of fibrolamellar hepatocarcinoma in young patients, and its lack of association with underlying liver disease. The clinical presentation is unspecific, with symptoms ranging from abdominal pain, malaise, and weight loss to atypical manifestation which include hyperammonemic encephalopathy. We present the case of a 33-year-old woman with no prior medical history who presented with a coma and a diagnosis of inoperable fibrolamellar hepatocarcinoma requiring a cadaver donor transplant. While she was on the waiting list, she received hemofiltration and ammonium benzoate treatment, with progressive improvement in her state of consciousness.","UNIVERSIDAD DEL ROSARIO"],"dc:format":["application/pdf"],"dc:identifier":["https://doi.org/10.48713/10336_18871","http://repository.urosario.edu.co/handle/10336/18871"],"dc:language":["spa"],"dc:publisher":["Universidad del Rosario","Facultad de Medicina","Especialización en Gastroenterología"],"dc:rights":["info:eu-repo/semantics/openAccess","http://creativecommons.org/licenses/by-nc-nd/2.5/co/"],"dc:source":["H.A.Edmondson,“Differentialdiagnosisoftumorsandtumorlikelesionsofliverininfancyandchildhood,”A.M.A.American JournalofDiseasesofChildren,vol.91,no.2,pp.168–186,1956.","V.Maniaci,B.R.Davidson,K.Rollesetal.,“Fibrolamellarhepatocellularcarcinoma-Prolongedsurvivalwithmultimodality therapy,”European Journal of Surgical Oncology, vol. 35,no. 6, pp.617–621,2009.","M.Torbenson,“FibrolamellarCarcinoma:2012Update,”Scientifica,vol.2012,ArticleID743790,15pages,2012.","E.J.GrossmanandJ.M.Millis,“Livertransplantationfornonhepatocellularcarcinomamalignancy:indications,limitations, andanalysisofthecurrentliterature,”LiverTransplantation,vol. 16,no.8,pp.930–942,2010.","V. Paradis, “Histopathology of hepatocellular carcinoma,” in Multidisciplinary Treatment of Hepatocellular Carcinoma, vol. 190 of Recent Results in Cancer Research, pp. 21–32, Springer, Berlin,Germany,2013.","G. M. Fonseca, A. D. Varella, F. F. Coelho, E. S. Abe, R. B. Dumarco, and P. Herman, “Downstaging and resection after neoadjuvant therapyfor fibrolamellar hepatocellularcarcinoma,”WorldJournalofGastrointestinalSurgery,vol.6,no.6, p.107,2014.","D.Ganeshan,J.Szklaruk,V.Kundra,A.Kaseb,A.Rashid,and K. Elsayes, “Imaging features of fibrolamellar hepatocellular carcinoma,”AmericanJournalofRoentgenology,vol.202,no.3, pp.544–552,2014.","T.Eggert,K.A.McGlynn,A.Duffy,M.P.Manns,T.F.Greten, andS.F.Altekruse,“Fibrolamellarhepatocellularcarcinomain theUSA,2000–2010:adetailedreportonfrequency,treatment andoutcomebasedonthesurveillance,epidemiology,andend Results database,” United European Gastroenterology Journal, vol.1,no.5,pp.351–357,2013.","H.Cornella,C.Alsinet,S.Sayolsetal.,“Uniquegenomicprofile of fibrolamellar hepatocellular carcinoma,” Gastroenterology, vol.148,no.4,pp.806–818.e10,2015.","G. G. Malouf, S. Job, V. Paradis et al., “Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrinesignature,”Hepatology,vol.59,no.6,pp.2228–2237, 2014.","T. Pawlik and K. Lafaro, “Fibrolamellar hepatocellular carcinoma: current clinical perspectives,” Journal of Hepatocellular Carcinoma,p.151.","T. Kanai, T. Takabayashi, Y. Kawano, S. Kuramochi, and N. Miyazawa,“Acaseofpostoperativerecurrenceoffibrolamellar hepatocellular carcinoma with increased vitamin B12 binding capacityinayoungJapanesefemale,”JapaneseJournalofClinical Oncology,vol.34,no.6,pp.346–351,2004.","S. K. Asrani and N. F. Larusso, “Fibrolamellar hepatocellular carcinoma presenting with budd-chiari syndrome, right atrial thrombus, and pulmonary emboli,” Hepatology, vol. 55, no. 3, pp.977-978,2012.","J.Lloreta,C.Vadell,X.Fabregat,andS.Serrano,“Fibrolamellar hepatictumorwithneurosecretoryfeaturesandsystemicdepositionofAAamyloid,”UltrastructuralPathology,vol.18,no.1-2, pp.287–292,1994.","J. A. Espinosa, A. Merlo, M.-O. Arafeh, and G. Munene, “An unusualcaseofjaundice:Biliarytumorthrombusinfibrolamellar hepatocellular carcinoma,” International Journal of Surgery CaseReports,vol.36,pp.50–54,2017.","K. M. Tezer, B. Yalc ¸´ın, N. B¨ uy¨ukpamukc¸u, G. Kale, and M. B¨uy¨ukpamukc¸u,“Fibrolamellarhepatocellularcarcinomawith skeletalmetastases,”PediatricHematologyandOncology,vol.18, no.4,pp.273–278,2001.","N.A.Villa,R.Pannala,D.O.Faigeletal.,“Metastaticfibrolamellar hepatocellular carcinoma to the pancreas,” Case Reports in Gastroenterology,vol.9,pp.266–271,2015.","S.H.Ciurea,E.Matei,C.S.Stanescuetal.etal.,“Fibrolamellar hepatocellularcarcinomawithovarianmetastasis-anunusual presentation.Rom,”JournalofMorphologyandEmbryology,vol. 58,pp.187-92,2017.","O.Soreide,A.Czemiak,H.Bradpiece,S.Bloom,andL.Blumgart,“Characteristicsoffibrolamellarhepatocellularcarcinoma. A study of nine cases and a review of the literature,” The AmericanJournalofSurgery,vol.151,no.4,pp.518–523,1986.","D. L. Lildballe, K. Q. T. Nguyen, S. S. Poulsen, H. O. Nielsen, and E. Nexo, “Haptocorrin as marker of disease progression infibrolamellarhepatocellularcarcinoma,”EuropeanJournalof SurgicalOncology,vol.37,no.1,pp.72–79,2011.","R. K. G. Do, A. McErlean, C. S. Ang, R. P. Dematteo, and G. K. Abou-Alfa, “CT and MRI of primary and metastatic fibrolamellar carcinoma: A case series of 37 patients,” British JournalofRadiology,vol.87,no.1040,ArticleID20140024,2014.","S. Liu, K. Wah Chan, J. Tong, Y. Wang, B. Wang, and L. Qiao, “PET-CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellularcarcinoma:A casereport and a summaryofrecentliterature,”QJM:AnInternationalJournalof Medicine,vol.104,no.6,pp.477–483,2011.","C.G.Roth andD.G.Mitchell,“Hepatocellularcarcinomaand otherhepaticmalignancies:MRimaging,”RadiologicClinicsof NorthAmerica,vol.52,no.4,pp.683–707,2014.","S. Sethi, N. Tageja, J. Singh et al., “Hyperammonemic encephalopathy:Ararepresentationoffibrolamellarhepatocellularcarcinoma,”TheAmericanJournaloftheMedicalSciences , vol.338,no.6,pp.522–524,2009.","C. Berger, P. Dimant, L. Hermida, F. Paulin, M. Pereyra, and M.Tejo,“Hyperammonemicencephalopathyandfibrolamellar hepatocellularcarcinoma,”Medicina(Argentina),vol.72,no.5, pp.425–427,2012.","R. A. Sulaiman and T. Geberhiwot, “Fibrolamellar Hepatocellular Carcinoma Mimicking Ornithine Transcarbamylase Deficiency,”inJIMDReportsVolume16,vol.16ofJIMDReports, pp.47–50,SpringerBerlinHeidelberg,Berlin,Heidelberg,2014.","C. I. Chapuy, I. Sahai, R. Sharma, A. X. Zhu, and O. N. Kozyreva,“Hyperammonemicencephalopathyassociatedwith fibrolamellar hepatocellular carcinoma: Case report, literature review,andproposedtreatmentalgorithm,”TheOncologist,vol. 21,no.4,pp.514–520,2016.","M. N. Mavros, S. C. Mayo, O. Hyder, and T. M. Pawlik, “A systematic review: Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma,” Journal of the AmericanCollegeofSurgeons,vol.215,no.6,pp.820–830,2012.","W. T. Kassahun, “Contemporary management of fibrolamellar hepatocellular carcinoma: Diagnosis, treatment, outcome, prognosticfactors,andrecentdevelopments,”WorldJournalof SurgicalOncology,vol.14,no.1,articleno.151,2016.","A. D. Pinna, S. Iwatsuki, R. G. Lee et al., “Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation,”Hepatology,vol.26,no.4,pp.877–883,1997.","L.G.Atienza,J.Berger,X.Meietal.,“Livertransplantationfor fibrolamellarhepatocellularcarcinoma:Anationalperspective,” JournalofSurgicalOncology,vol.115,no.3,pp.319–323,2017.","A.O.Kaseb,M.Shama,I.H.Sahinetal.,“Prognosticindicators and treatmentoutcome in94 casesof fibrolamellar hepatocellularcarcinoma,”Oncology(Switzerland),vol.85,no.4,pp.197– 203,2013.","B. Njei, “Fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: Better 5-year survival or artifactualresultofresearchmethodology?”Gut,vol.63,no.9, pp.1374-1375,2014","A. E. Alsina, “Successful Liver Transplantation for HyperammonemicFibrolamellarHepatocellularCarcinoma,”ACGCase ReportsJournal,vol.3,no.4,2016","instname:Universidad del Rosario","reponame:Repositorio Institucional EdocUR"],"dc:subject":["Fibrolamellar hepatocellular carcinoma","Noncirrhotic hyperammonemic encephalopathy","Enfermedades","Hepatocarcinoma fibrolamelar","Enfermedades hepáticas"],"dc:title":["Fibrolamellar Hepatocellular Carcinoma and Noncirrhotic Hyperammonemic Encephalopathy"],"dc:type":["info:eu-repo/semantics/masterThesis","info:eu-repo/semantics/acceptedVersion"]},"updated_at":"2026-07-27T20:46:13Z"}